FindTrial
Sign In

Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas

Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT07218224
Enrollment
Unknown
Registered
2025-10-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parathyroid Adenomas

Brief summary

This expanded access protocol is proposed to allow University of California San Francisco (UCSF) patients additional access to 18F-fluorocholine (FCH) Positron Emission Tomography (PET) imaging for localization of parathyroid adenomas.

Detailed description

No health outcome measures will be obtained under this protocol.

Interventions

DRUG18F-Fluorocholine (FCH)

A dose of 4-7 millicurie (mCi) +/- 10% of radiotracer 18F-Fluorocholine (FCH) manufactured at UCSF will be given intravenously.

PROCEDUREPositron emission tomography (PET)

A scan is a procedure that produces images of organs and tissues used in conjunction with a radiotracer.

Sponsors

Thomas Hope
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
13 Years to No maximum

Inclusion criteria

1. Age ≥ 13 years. 2. Evidence of primary hyperparathyroidism. 3. Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion criteria

1\. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.

Contacts

Primary ContactMaya Aslam
maya.aslam@ucsf.edu(415)514-8987

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026